KEY FEATURES 

Therapeutic Class: Investigational peptide therapy

Mechanism of Action: Triple receptor agonist (GIP, GLP‑1, glucagon)
Primary Uses (Investigational): Obesity management, metabolic regulation, type 2 diabetes (under study)

Clinical Benefits (Trial Data):

Up to 24–25% body weight reduction in <1 year

Improved glucose metabolism and insulin sensitivity
Appetite suppression and increased energy expenditure
Status: Not FDA‑approved; currently in Phase II/III clinical trials

TECHNICAL SPECIFICATIONS 

Molecular Type: Synthetic peptide (LY‑3437943)

Administration Route: Subcutaneous injection (once weekly)
Formulation: Prefilled injection pens (trial use)
Stability & Storage: Refrigerated until use; stability data under investigation

Safety Profile (Investigational):

GI side effects (nausea, diarrhea)

Risks under study: bone health, kidney complications, rapid weight loss

Regulatory Identifiers: Not yet assigned ATC code or HS classification (pending approval)

AVAILABLE CONFIGURATIONS 

Format & Delivery:

Prefilled injection pens (trial formulations)

Bulk API (research supply only)

Concentration & Dosing:

Investigational fixed strengths (dose escalation in trials)

No commercial dosing yet established

Packaging & Labeling:

Clinical trial packaging only

Future potential: finished product packaging, private labeling (post‑approval)